Sugiura Hideshi, Yamada Kenji, Sugiura Takahiko, Hida Toyoaki, Mitsudomi Tetsuya
Department of Orthopaedic Surgery, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, Japan.
Clin Orthop Relat Res. 2008 Mar;466(3):729-36. doi: 10.1007/s11999-007-0051-0. Epub 2008 Jan 3.
The prognosis of patients with bone metastasis from lung cancer has not been well documented. We assessed the survival rates after bone metastasis and prognostic factors in 118 patients with bone metastases from lung cancer. The cumulative survival rates after bone metastasis from lung cancer were 59.9% at 6 months, 31.6% at 1 year, and 11.3% at 2 years. The mean survival was 9.7 months (median, 7.2 months; range, 0.1-74.5 months). A favorable prognosis was more likely in women and patients with adenocarcinoma, solitary bone metastasis, no metastases to the appendicular bone, no pathologic fractures, performance status 1 or less, use of systemic chemotherapy, and use of an epithelial growth factor receptor inhibitor. Analyses of single and multiple variables indicated better prognoses for patients with adenocarcinoma, no evidence of appendicular bone metastases, and treatment with an epithelial growth factor receptor inhibitor. The mean survival period was longer in a small group treated with an epithelial growth factor receptor inhibitor than in the larger untreated group. The data preliminarily suggest treatment with an epithelial growth factor receptor inhibitor may improve survival after bone metastasis.
肺癌骨转移患者的预后情况尚无充分记录。我们评估了118例肺癌骨转移患者骨转移后的生存率及预后因素。肺癌骨转移后的累积生存率在6个月时为59.9%，1年时为31.6%，2年时为11.3%。平均生存期为9.7个月（中位数为7.2个月；范围为0.1 - 74.5个月）。女性、腺癌患者、单发骨转移、无四肢骨转移、无病理性骨折、体能状态为1或更低、接受全身化疗以及使用上皮生长因子受体抑制剂的患者预后更有利。单变量和多变量分析表明，腺癌患者、无四肢骨转移证据以及接受上皮生长因子受体抑制剂治疗的患者预后较好。接受上皮生长因子受体抑制剂治疗的一小部分患者的平均生存期比未接受治疗的较大组更长。数据初步表明，使用上皮生长因子受体抑制剂治疗可能会改善骨转移后的生存率。
